Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

CSPC Pharmaceuticals

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

- PMLiVE

AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

The company will gain a novel oral treatment for lung cancer

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes

The insulin is designed as an alternative to daily basal insulin

- PMLiVE

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Novo Nordisk announces positive results for CagriSema in type 2 diabetes

CagriSema improved weight loss and blood glucose control compared to semaglutide alone across all tested doses

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030

The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China

- PMLiVE

Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity

Obesity affects approximately 15 million people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links